Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clotbusting On The Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do

Executive Summary

FDA's three-month postponement of a decision on AstraZeneca PLC’s NDA for Brilinta (ticagrelor) may signal more trouble for the long-term viability of the product rather than any concern about its actual approvability.
Advertisement

Related Content

AstraZeneca's Brilique Approved In The EU
GRAVITAS Fails To Show Clinical Value Of Platelet Function Testing For Plavix
AstraZeneca's Ticagrelor Gets Positive EU Recommendation, But FDA Could Catch Up Soon
Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care Test Filed
Low-Dose Aspirin Label Could Pose High Commercial Hurdle For Brilinta
Low-Dose Aspirin Label Could Pose High Commercial Hurdle For Brilinta

Topics

Advertisement
UsernamePublicRestriction

Register

PS052624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel